• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of August 26


The Center for Biosimilars® recaps the top stories for the week of August 26, 2019.


Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 26, 2019.

Number 5: A new report shows that employers could see substantial savings from biosimilars, but those savings won’t come without a concerted effort to encourage biosimilar use.

Number 4: The International Coalition of Medicines Regulatory Authorities has released a statement of confidence in biosimilars.

Number 3: According to the Centers for Disease Control and Prevention, women are more likely than men not to take their diabetes medications as prescribed in an effort to save on high drug costs.

Number 2: A recent cost simulation found that, when taking on-body device failure into account, biosimilar filgrastim has better cost efficiency than Neulasta.

Number 1: A new treatment guideline for axial spondyloarthritis strongly recommends that stable patients not be required to switch to a biosimilar.

Finally, last week, our e-newsletter asked whether you think that oncology biosimilars are on a better road to US uptake than biosimilars that treat inflammatory diseases.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
GBW 2023 webinar
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.